CN112041338A - 嗜酸性粒细胞病症的基因疗法 - Google Patents

嗜酸性粒细胞病症的基因疗法 Download PDF

Info

Publication number
CN112041338A
CN112041338A CN201880090512.8A CN201880090512A CN112041338A CN 112041338 A CN112041338 A CN 112041338A CN 201880090512 A CN201880090512 A CN 201880090512A CN 112041338 A CN112041338 A CN 112041338A
Authority
CN
China
Prior art keywords
antibody
seq
polypeptide
eosinophil
eosinophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880090512.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·G·克雷斯托
O·E·帕格维齐
K·斯泰尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN112041338A publication Critical patent/CN112041338A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880090512.8A 2017-12-29 2018-12-28 嗜酸性粒细胞病症的基因疗法 Pending CN112041338A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762612005P 2017-12-29 2017-12-29
US62/612,005 2017-12-29
PCT/US2018/067869 WO2019133818A1 (en) 2017-12-29 2018-12-28 Gene therapy for eosinohilic disorders

Publications (1)

Publication Number Publication Date
CN112041338A true CN112041338A (zh) 2020-12-04

Family

ID=65324530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880090512.8A Pending CN112041338A (zh) 2017-12-29 2018-12-28 嗜酸性粒细胞病症的基因疗法

Country Status (10)

Country Link
US (1) US20200330608A1 (pt)
EP (1) EP3732194A1 (pt)
JP (2) JP2021508719A (pt)
KR (1) KR20200105494A (pt)
CN (1) CN112041338A (pt)
AU (1) AU2018394940A1 (pt)
BR (1) BR112020012830A2 (pt)
CA (1) CA3087063A1 (pt)
IL (1) IL275613A (pt)
WO (1) WO2019133818A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061032A1 (en) * 2020-09-17 2022-03-24 Allakos Inc. Methods and compositions for treating viral infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267973A1 (en) * 2004-06-09 2008-10-30 Genetech, Inc. Diagnosis and Treatment of Siglec-6 Associated Diseases
CN101848732A (zh) * 2007-05-14 2010-09-29 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
US20160296638A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
US20170073413A1 (en) * 2014-02-28 2017-03-16 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US20030099995A1 (en) 1998-02-09 2003-05-29 Incyte Genomics, Inc. Ras association domain containing protein
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2003220525A1 (en) * 2002-03-29 2003-10-20 Abgenix, Inc. Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267973A1 (en) * 2004-06-09 2008-10-30 Genetech, Inc. Diagnosis and Treatment of Siglec-6 Associated Diseases
CN101848732A (zh) * 2007-05-14 2010-09-29 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
US20170073413A1 (en) * 2014-02-28 2017-03-16 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
US20160296638A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
N. ZIMMERMANN等: "《Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils》", 《ALLERGY》 *
N. ZIMMERMANN等: "《Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils》", 《ALLERGY》, vol. 63, no. 9, 30 September 2008 (2008-09-30), pages 1 - 5 *
王学林主编: "《抗病毒药物分子药理》", 《分子药理学》 *
王学林主编: "《抗病毒药物分子药理》", 《分子药理学》, 30 June 2011 (2011-06-30), pages 1 *

Also Published As

Publication number Publication date
US20200330608A1 (en) 2020-10-22
EP3732194A1 (en) 2020-11-04
BR112020012830A2 (pt) 2021-01-26
IL275613A (en) 2020-08-31
JP2021508719A (ja) 2021-03-11
AU2018394940A1 (en) 2020-08-13
JP2023179525A (ja) 2023-12-19
WO2019133818A1 (en) 2019-07-04
WO2019133818A8 (en) 2020-09-24
CA3087063A1 (en) 2019-07-04
KR20200105494A (ko) 2020-09-07

Similar Documents

Publication Publication Date Title
US20200172605A1 (en) Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
JP7390693B2 (ja) 抗体回避性ウイルスベクターのための方法および組成物
ES2946747T3 (es) Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis
AU2017345470B2 (en) Modified AAV capsids and uses thereof
JP6983511B2 (ja) 脳中の転移乳癌および他の癌を処置するための方法および組成物
US20210130413A1 (en) Modified aav capsids and uses thereof
AU2017257169B2 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
JP7428664B2 (ja) 合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
BR112019019158A2 (pt) composições e métodos para expressão genética melhorada
JP2018515096A (ja) 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
JP2020528734A (ja) バリアントカプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
JP7303816B2 (ja) Ａａｖベクター
TW202110869A (zh) 修飾之病毒顆粒及其用途
JP2020062038A (ja) 多発性硬化症のためのａａｖ系遺伝子療法
JP2023179525A (ja) 好酸球性障害のための遺伝子療法
KR20230117179A (ko) 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법
JP2023526587A (ja) 改変型上皮成長因子受容体及び細胞追跡におけるその使用
WO2017120589A1 (en) Compositions comprising chemerin and methods of use thereof
WO2023178171A2 (en) Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
JP2024504926A (ja) がんの処置のためのデオキシリボヌクレアーゼ酵素と細胞療法の組み合わせ
CN116568283A (zh) 用于治疗前庭神经鞘瘤相关症状的抗vegf抗体构建体和相关方法
KR20230049618A (ko) 면역 조정인자를 갖는 세포외 소포

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination